Correlation Between Elevation Oncology and Mereo BioPharma
Can any of the company-specific risk be diversified away by investing in both Elevation Oncology and Mereo BioPharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Elevation Oncology and Mereo BioPharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Elevation Oncology and Mereo BioPharma Group, you can compare the effects of market volatilities on Elevation Oncology and Mereo BioPharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Elevation Oncology with a short position of Mereo BioPharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Elevation Oncology and Mereo BioPharma.
Diversification Opportunities for Elevation Oncology and Mereo BioPharma
0.44 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Elevation and Mereo is 0.44. Overlapping area represents the amount of risk that can be diversified away by holding Elevation Oncology and Mereo BioPharma Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mereo BioPharma Group and Elevation Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Elevation Oncology are associated (or correlated) with Mereo BioPharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mereo BioPharma Group has no effect on the direction of Elevation Oncology i.e., Elevation Oncology and Mereo BioPharma go up and down completely randomly.
Pair Corralation between Elevation Oncology and Mereo BioPharma
Given the investment horizon of 90 days Elevation Oncology is expected to under-perform the Mereo BioPharma. In addition to that, Elevation Oncology is 1.84 times more volatile than Mereo BioPharma Group. It trades about -0.06 of its total potential returns per unit of risk. Mereo BioPharma Group is currently generating about 0.0 per unit of volatility. If you would invest 379.00 in Mereo BioPharma Group on August 28, 2024 and sell it today you would lose (41.00) from holding Mereo BioPharma Group or give up 10.82% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Elevation Oncology vs. Mereo BioPharma Group
Performance |
| Timeline |
| Elevation Oncology |
| Mereo BioPharma Group |
Elevation Oncology and Mereo BioPharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Elevation Oncology and Mereo BioPharma
The main advantage of trading using opposite Elevation Oncology and Mereo BioPharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Elevation Oncology position performs unexpectedly, Mereo BioPharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will offset losses from the drop in Mereo BioPharma's long position.| Elevation Oncology vs. Eliem Therapeutics | Elevation Oncology vs. HCW Biologics | Elevation Oncology vs. Scpharmaceuticals | Elevation Oncology vs. Milestone Pharmaceuticals |
| Mereo BioPharma vs. Eliem Therapeutics | Mereo BioPharma vs. HCW Biologics | Mereo BioPharma vs. Scpharmaceuticals | Mereo BioPharma vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Complementary Tools
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |